H
Hirohisa Yoshizawa
Researcher at Niigata University
Publications - 93
Citations - 8510
Hirohisa Yoshizawa is an academic researcher from Niigata University. The author has contributed to research in topics: Lung cancer & Gefitinib. The author has an hindex of 28, co-authored 92 publications receiving 7766 citations.
Papers
More filters
Journal ArticleDOI
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Makoto Maemondo,Akira Inoue,Kunihiko Kobayashi,Shunichi Sugawara,Satoshi Oizumi,Hiroshi Isobe,Akihiko Gemma,Masao Harada,Hirohisa Yoshizawa,Ichiro Kinoshita,Yuka Fujita,Shoji Okinaga,Haruto Hirano,Kozo Yoshimori,Toshiyuki Harada,Takashi Ogura,Masahiro Ando,Hitoshi Miyazawa,Tomoaki Tanaka,Yasuo Saijo,Koichi Hagiwara,Satoshi Morita,Toshihiro Nukiwa +22 more
TL;DR: First-line gefitinib for patients with advanced non-small-cell lung cancer who were selected on the basis of EGFR mutations improved progression-free survival, with acceptable toxicity, as compared with standard chemotherapy.
Journal ArticleDOI
Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)
Akira Inoue,Kazuhiko Kobayashi,Makoto Maemondo,Shunichi Sugawara,Satoshi Oizumi,Hiroaki Isobe,Akihiko Gemma,Masao Harada,Hirohisa Yoshizawa,Ichiro Kinoshita,Yuka Fujita,Shoji Okinaga,H. Hirano,Kozo Yoshimori,Toshiyuki Harada,Yasuo Saijo,Koichi Hagiwara,Satoshi Morita,Toshihiro Nukiwa +18 more
TL;DR: Considering the many benefits and the risk of missing an opportunity to use the most effective agent for EGFR-mutated NSCLC, the first-line gefitinib is strongly recommended.
Journal ArticleDOI
Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial
Mitsue Saito,Kenjiro Aogi,Ikuo Sekine,Hirohisa Yoshizawa,Yasuhiro Yanagita,Hiroshi Sakai,Kenichi Inoue,Chiyoe Kitagawa,Takashi Ogura,Shoichi Mitsuhashi +9 more
TL;DR: This phase III, multicentre, randomised, double-dummy, stratified, parallel-group, active-comparator trial assessed the efficacy and safety of palonosetron versus granisetron for chemotherapy-induced nausea and vomiting.
Journal ArticleDOI
Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis.
Satoshi Watanabe,Junta Tanaka,Takeshi Ota,Rie Kondo,Hiroshi Tanaka,Hiroshi Kagamu,Kosuke Ichikawa,Jun Koshio,Junko Baba,Takao Miyabayashi,Ichiei Narita,Hirohisa Yoshizawa +11 more
TL;DR: The results indicate that a 2nd EGFR-TKI treatment can be an effective treatment option for gefitinib responders and are generally acceptable and comparable to those observed for the initial gefithinib therapy.
Journal ArticleDOI
Eradication of established tumors in mice by a combination antibody-based therapy.
Tomoyasu Uno,Kazuyoshi Takeda,Kazuyoshi Takeda,Yuko Kojima,Hirohisa Yoshizawa,Hisaya Akiba,Robert S. Mittler,Fumitake Gejyo,Ko Okumura,Hideo Yagita,Mark J. Smyth +10 more
TL;DR: Results in mice indicate that a rational monoclonal antibody-based therapy that both causes tumor-cell apoptosis through DR5 and activates T cells may be an effective strategy for cancer immunotherapy in humans.